|
|
 |
|
Viewing report
|
|
|
|
Pharmaceutical M&A in the Asia Pacific Region
Datamonitor, Nov 2011, Pages: 72
Slowing growth continues in major developed markets, prompted by generic erosion of branded sales and increasing regulatory and cost containment pressures. Expansion into emerging Asia Pacific (APAC) markets is appealing not only because of their rapid growth and sizeable patient populations, but also because operating environments are improving as these countries open up to global trade.
Features and benefits
- Overview of drivers, resistors and trends within the Asia Pacific M&A landscape.
- Summary of geographic M&A activity on a regional and country-specific basis.
- Analysis of the types of acquisitions and healthcare sectors targeted.
- Examination of transaction values and leading dealmakers.
Highlights
- India, Japan and Australia all continued to record frequent deal activity, although China increased its lead in terms of total deal numbers in 2010 and early 2011. However, Chinese companies continue to focus primarily on domestic transactions.
- Japanese companies still account for the majority of M&A deal value. The first half of 2011 has already surpassed previous peak M&A deal values in APAC, continuing the annual upward trend seen in transaction values when outlying multi-billion dollar deals are excluded.
- While most M&As involving APAC-based players target pharmaceutical and biological products companies, such as generics and active pharmaceutical ingredient (API) manufacturers, medical devices and equipment firms have recently taken over as the leading sector targeted for M&A.
Your key questions answered
- Which are the most highly valued pharmaceutical sectors for acquirers, and which companies have been the most acquisitive in APAC in recent years?
- Which APAC markets have been most frequently targeted through M&As, and which have attracted the attention of Big Pharma?
|
|
|
|
